News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hyperion Therapeutics Announces Health Canada Accepts RAVICTI® New Drug Submission With Priority Review


6/3/2014 9:16:56 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BRISBANE, Calif., June 3, 2014 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that the validation period is complete for its New Drug Submission (NDS) to Health Canada for RAVICTI (glycerol phenylbutyrate) Oral Liquid for the treatment of urea cycle disorders (UCDs), and that the RAVICTI NDS was granted Priority Review. Standard review in Canada takes 18 months or more and Priority Review, which is granted to promising medicines that address life-threatening or severely debilitating conditions, shortens the review time to approximately six months.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES